OXLUMO® (lumasiran) is a subcutaneous injection dosed by weight. Find more information on dosing and administration here. OXLUMO® is an FDA‐approved treatment for primary hyperoxaluria type 1 …

Apr 7, 2025 · Detailed dosage guidelines and administration information for Oxlumo Injection (lumasiran). Includes dose adjustments, warnings and precautions.

OXLUMO® (lumasiran) subcutaneous injection is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.1

OXLUMO® (lumasiran) is the first FDA-approved prescription medication for the treatment of primary hyperoxaluria type 1 (PH1) by lowering oxalate in urine. See Important Safety Information on risk of …

OXLUMO®(lumasiran) is administered via subcutaneous injection by a healthcare professional, based on actual body weight. Administer treatment as soon as possible. Resume prescribed monthly or …

Dec 1, 2025 · OXLUMO (lumasiran) injection, for subcutaneous use ... OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in …

Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups. Therapy should be initiated and supervised by a physician experienced in the management of hyperoxaluria. …

Administer subcutaneous injection into the abdomen, thigh, or the side or back of the upper arms. Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or...

Patients received the recommended dosing regimen of OXLUMO based on body weight [see Dosage and Administration (2.1)]. Patients requiring peritoneal dialysis were excluded.

Apr 15, 2025 · Administer subcutaneous injection into the abdomen, thigh, or the side or back of the upper arms. Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, …